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1. Introduction  
Fibromyalgia syndrome (FS) is a common musculo-skeletal disorder characterized by 
otherwise unexplained chronic widespread pain, a lowered pain threshold, high tender 
point counts (tenderness on examination at specific, predictable anatomic sites known as 
tender points), sleep disturbances, fatigue, headache, irritable bowel syndrome, morning 
stiffness, paraesthesias in the extremities, often psychological distress and depressed mood 
(Mease, 2005).  
The diagnosis of FS is based on a history of widespread pain, defined as bilateral, upper and 
lower body, as well as spine, and the presence of excessive tenderness on applying pressure 
to 11 of 18 specific muscle-tendon sites (Wolfe et al., 1990). The 1990 American College of 
Rheumatology (ACR) classification criteria for the diagnosis of FS provide a sensitivity and 
specificity of nearly 85% in differentiating FS from other forms of chronic musculoskeletal 
pain. According to these criteria, FS can be diagnosed in about 2-3% in the United States 
population, with a prevalence in women of 3.4% and in men of about 0.5% (Wolfe & Cathey, 
1983). The most recent data from US describes FS as the third most prevalent rheumatic 
disease, after low back pain and osteoarthritis (Lawrence et al., 2008). 
FS has a negative impact on quality of life (QoL), working capacity, family life and social 
functioning. Significantly higher total healthcare costs have been reported among patients 
diagnosed with FS compared to the general population (Spaeth, 2009); in fact, FS patients 
incur high direct medical costs and significant indirect costs (e.g. disability pension, 
absenteeism). Effective treatment options are therefore needed for medical and economic 
reasons.  
Because of the unknown aetiology and the unclear pathogenesis, there is no standard 
therapy regime for FS. In recent years, at least three sets of guidelines have been developed 
by different medical organizations in an attempt to standardize the treatment of this 
condition (American Pain Society, European League Against Rheumatism, Association of 
the Medical Society of Germany) (Goldenberg et al., 2004 ; Carville et al., 2008 ; Klement et 
al., 2008). The current recommendations suggest that the optimal treatment of FS requires a 
multidisciplinary approach with a combination of non-pharmacological and 
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pharmacological treatment modalities tailored according to pain intensity, function, 
associated features, such as depression, fatigue and sleep disturbances, decided through 
discussion with the patient. A variety of medical treatments, including antidepressants, 
opioids, analgesics, non-steroidal anti-inflammatory drugs (NSAIDs), sedatives, muscle 
relaxants and antiepileptics have been used to treat FS (Goldenberg et al., 2004 ; Carville et 
al., 2008 ; Klement et al., 2008). Given the complexity and chronicity of FS and the relatively 
poor response to pharmacological treatments, it is not surprising that patients often resort to 
complementary or alternative therapies (Sarac & Gur, 2006). Non-pharmaceutical treatment 
modalities, including exercise, physical therapy, massage, acupuncture, osteopathic 
manipulation, patient education and cognitive behavioural therapy can be helpful 
(Goldenberg et al., 2004 ; Carville et al., 2008 ; Klement et al., 2008). Spa therapy is one of the 
most commonly used non-pharmacological approaches for FS in many European countries, 
as well as in Japan and Israel. Spa therapy comprises a broad spectrum of therapeutic 
options including hydrotherapy, balneotherapy, physiotherapy, mud-pack therapy and 
exercise (Sukenik et al., 1999; Bender et al., 2005). However, despite their long history and 
popularity, spa treatments are still the subject of debate and their role in modern medicine is 
still not clear (Verhagen et al., 2000). We summarize the currently available information on 
clinical effects and mechanism of action of  spa therapy in FS.  
2. Randomized clinical trials (RCTs) on spa therapy in FS 
We conducted a search of the literature in April 2011. In an attempt to standardize the 
patient sample included, the search was conducted from 1990 (the date of publication of the 
ACR classification criteria for FS) to April 2011. Medline was searched using the term 
“randomized clinical trial”, “spa therapy”, “mud” and “balneotherapy” in combination with 
FS. RCTs written in languages other than English were excluded from the search.  
We identified eight assessable articles reporting 7 RCTs on spa therapy in FS, including a 
total number of patients of 314 (TABLE 1). Over 90% of the participants in the studies were 
women. All studies were blind with an “assessor” blind to the type of treatment. In five 
studies mineral baths were used, in one study bathing was combined with exercise 
treatment, one study evaluated the effect of spa therapy and one study the effect of mud-
pack treatment. 
Yurtkuran et al. (Yurtkuran et al., 1996) investigated the effect of the addition of 
balneotherapy to relaxation exercises in 40 patients with FS. The study was conducted in a 
daily living environment and the treatment duration was 2 weeks. Patients taking part in 
the balneotherapy program bathed at 37°C for 20 min a day, 5 days per week followed by 
relaxation exercises. Patients in the control group received only relaxation exercises. Pain 
relief, as scored by Visual Analogue Scale (VAS), was achieved in both groups at the end of 
therapy and persisted for 6 weeks; however, significant improvements in mean Pressure 
Algometric Scores (PAS) during follow-up were only observed in the balneotherapy group.  
Buskila et al. (Buskila et al., 2001) and Neumann et al. (Neumann et al., 2001) reported the 
beneficial effect of Dead Sea balneotherapy on FS-related symptoms and QoL index in 
patients with FS. In this study 48 patients with FS were randomly assigned to treatment and 
control groups of 24 subjects each. The patients in the treatment group bathed for 20 min per 
day in a sulphur pool at 37°C for 10 days, while the control group did not receive this  
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Authors 
Sample 
size 
Intervention 
Outcome 
measures 
Follow-up Results 
Yurtkuran 
1996 
A: 20 
B: 20 
A:Balneotherapy+ 
exercises 
 
B:Excercises only
VAS, PAS 6 weeks 
Significant changes on VAS and 
PAS for group A at the end of 
treatment and at 6 weeks 
Buskila 
2001 
A: 24 
B: 24 
A: Balneotherapy
 
 
B: No treatment 
VAS (Pain and 
other  minor 
symptoms), 
FIQ,  TPC,  
Dolorimeter, 
FDI
3 months 
Significant between group 
improvements in pain and TPC 
in favour of A. Still seen after 3 
months 
Neumann 
2001 
A: 24 
B: 24 
A: Balneotherapy
 
B: No treatment 
SF36, AIMS, 
VAS (Pain and 
other minor 
symptoms), 
3 months 
Significant improvement in 
most subscales of the SF36 for 
both groups. The improvement 
in physical components of the 
QoL index lasted 3 months, 
whereas improvement in 
measures of psychological well-
being was of shorter duration. 
Subjects in  group A reported 
greater and longer-lasting 
improvement than subjects in 
the group B 
Evcik 
2002 
A: 22 
B: 20 
A: Balneotherapy
 
B: No treatment 
VAS, FIQ, 
TPC, BDI 
6 months 
The group  A showed 
statistically significant 
improvements in TPC, VAS, FIQ 
and BDI  at the end of  the 
therapy and this improvement  
persisted at 6 months  except for 
BDI 
Dönmez 
2005 
A: 16 
B: 14 
A :Spa therapy 
 
B: No treatment 
VAS (Pain and 
other  minor 
symptoms), 
FIQ,  TPC, 
BDI 
9 months 
Significant improvements in  
pain, TPC and FIQ for group A. 
The pain and TPC results 
persisted for up to one month 
and the FIQ results for up to 6 
months 
Ardiç 
2007 
A: 12 
B: 12 
A: Balneotherapy
 
B: No treatment 
 
VAS, TPC, 
FIQ, BDI 
3 weeks 
Statistically  significant 
improvement in VAS, BDI, TPC 
and FIQ was only found in 
group  A at the end of the 
treatment cycle 
Fioravanti 
2007 
A: 40 
B: 40 
A:  Mud -packs 
and Baths 
 
B: No treatment 
FIQ, TPC, 
VAS (Pain and 
other  minor 
symptoms), 
AIMS, HAQ 
16 weeks 
In group A, a significant 
improvement in all parameters 
was recorded after mud-bath 
therapy and after 16 weeks 
Özkurt 
2011 
A: 25 
B: 25 
A: Balneotherapy
 
B: No treatment 
VAS, FIQ, 
BDI, PGA, 
IGA, 
SF-36, TPC 
3 months 
Statistically significant 
improvement was recorded  in  
group  A for all outcome 
parameters at the end of the 
treatment cycle and after 3 
months, except for BDI and IGA 
Table 1. RCTs on SPA Therapy in FS (1996-2011) 
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treatment. All participants stayed in the Dead Sea area for 10 days and continued their 
regular medications for FS. Physical functioning, assessed by the Fibromyalgia Impact 
Questionnaire (FIQ),  FS-related symptoms, assessed by VAS, Functional Disability Index 
(FDI), Health Assessment Questionnaire (HAQ), tenderness measurements (Tender Point 
Count [TPC] and dolorimetry) and QoL index (Short Form-36 [SF36] and Arthritis Impact 
Measurement Scales [AIMS]) were recorded at basal time, at the end of treatment and 1 
month and 3 months later. Physical functioning and tenderness improved moderately in 
both groups. With the exception of tenderness threshold, the improvement was especially 
evident in the treatment group and even persisted beyond 3 months. Relief in the severity of 
FS-related symptoms (pain, fatigue, stiffness) and reduced frequency of symptoms 
(headache, sleep problems and subjective joint swelling) were reported in both groups, but 
lasted longer in the treatment group. Significant improvement in most subscales of the SF36 
was reported for both groups. Interestingly, the improvement in physical components of the 
QoL index usually lasted 3 months, whereas improvement in measures of psychological 
well-being was of shorter duration. Subjects in the balneotherapy group reported greater 
and longer-lasting improvement than subjects in the control group. Improvements in the 
control group were explained by temporary changes in lifestyle combined with the relaxed 
atmosphere of the Dead Sea resort. 
Evcik et al. (Evcik et al., 2002) also reported significant improvements lasting up to 6 months 
in patients treated with balneotherapy. In this study 42 patients with FS were randomly 
assigned to two groups. One group (22 patients) bathed for 20 min at 36°C once a day, five 
times per week for 3 consecutive weeks (total 15 sessions) and the other group (20 patients) 
continued their regular medications without balneotherapy. Patients were evaluated by 
TPC, VAS for pain, Beck’s Depression Index (BDI) and FIQ at basal time, after therapy and 6 
months later. The balneotherapy group showed statistically significant improvements in 
TPC, VAS score, FIQ and BDI values at the end of therapy; at 6 months, the improvement in 
all parameters except BDI persisted.  
A study by Donmez et al. (Donmez et al., 2005) compared the effects of a stay at a spa centre 
plus balneotherapy and the effects of regular care (control), recording significant 
improvements in major outcome measures, such as pain, TPC and FIQ with respect to 
control. The pain and TPC results persisted for up to one month and the FIQ results for up 
to 6 months. However, they could also be attributed to the effects of the spa stay (not offered 
to controls, who continued their habitual medical treatment and/or daily exercises). 
Ardiç et al. (Ardiç et al., 2007) investigated the clinical effects of balneotherapy in the 
treatment of FS, considering serum levels of certain inflammatory markers. One group of 
patients (n22) bathed 20 min per day for five days per week for three consecutive weeks 
and the other group (n22) (control) continued with pharmacological treatment. A 
statistically significant improvement in algometric score, VAS, BDI, TPC and FIQ was only 
found in the balneotherapy group at the end of the treatment cycle.  
In a  multicentric single-blind RCT study, Fioravanti et al. (Fioravanti et al., 2007) assessed 
the effects of a combination of mud packs and thermal baths (with two types of mineral 
water) on patients with primary FS who responded poorly to pharmacological therapy. 
They also analysed tolerance to mud packs, since no trial using this thermal treatment has 
been performed in FS. Eighty patients with primary FS were randomly allocated to two 
groups: 40 underwent a cycle of 12 mud packs and thermal baths over a period of 2 weeks, 
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40 were enrolled as controls and continued their regular outpatient care routine. Because 
many other non-specific factors may also contribute to the effects observed after spa 
therapy, including changes in the environment, pleasant scenery and the absence of work 
duties, in order to temper these factors, all patients lived near the spa, continued working 
and did not modify their lifestyles. Another aspect that often amplifies the effects of spa 
therapy is its frequent association with physio-kinesiotherapy. These treatments were 
excluded from the protocol if they had not yet begun and were not already established. The 
following parameters were evaluated at baseline, after thermal treatment and after 16 
weeks: FIQ, TPC, VAS for “minor” symptoms, AIMS1 and HAQ. Controls were assessed at 
the same intervals. A significant improvement in all parameters was recorded after mud-
pack therapy and after 16 weeks.  
Figure 1 shows  that the patients submitted to mud-bath therapy  underwent  an evident  
improvement of VAS score at the end of the cycle of the thermal treatment cycle (T1) and  
this improvement remained significant  after a follow-up period of 16  weeks (T2). 
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Fig. 1. VAS  score (mean  SD) at basal time (T0), after 2 weeks (T1) and 16 weeks  (T2) in 
mud-bath treated patients (MBT) and in controls (C). From Fioravanti et al., Rheumatol Int 
2007 
Figure 2 demonstrates that TPC  significantly was reduced at the end of the spa therapy 
cycle and remained stable after 16 weeks in comparison to baseline  only in patients treated 
with mud-bath therapy. 
The results were similar for the two types of mineral water. Regarding tolerance mud packs, 
no patient reported any exacerbation of symptoms and the hot applications were well 
tolerated by all. No drop-outs occurred during spa therapy and all patients completed the 
study. 
A recent RCT by Özkurt et al. (Özkurt et al., 2011) of 50 woman with FS confirmed the 
efficacy of balneotherapy on major outcome measures such as pain, FIQ, BDI, Patient’s and 
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Investigator’s Global Assessment (PGA and IGA) scores, and SF36. The results were 
maintained for up to 3 months, except for BDI and investigator’s global assessment score. 
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Fig. 2. Tender Point Count (mean  SD) at basel time (T0), after 2 weeks (T1) and 16 weeks 
(T2) in mud-bath treated patients (MBT) and in controls (C). From Fioravanti et al. 
Rheumatol Int 2007 
These various RCTs on spa therapy for FS suggest a positive effect on pain, other FS-related 
symptoms and QoL (McVeigh et al., 2008; Langhorst et al., 2009). The studies assessed the 
medium-long-term effect and found that the clinical efficacy of spa therapy lasted for 4-6 
months. Despite low tolerance of physical treatments by FS patients, spa therapy seems to 
be well tolerated and to have a lower percentage of side effects, which are also less severe, 
than those associated with pharmacological treatments.  
Some aspects of the studies on spa therapy for FS are disputable and could be a source of 
bias, for example the lack of double-blind experimental design due to the difficulty of 
creating a placebo with the same characteristics as the treatment. The methodological 
quality of the RCTs analysed was limited for the following reasons:  1) only two studies had 
a sample size of at least 25 per group, the number recognized as appropriate for detecting 
clinically significant differences between two active treatments (Chambless & Holton,  1998);  
2) no study included intention-to-treat analysis, but analysed the completers, possibly 
favouring the results of spa therapy, even if the drop-out rates were low;  3) most studies 
did not report the method of randomization used;  4) the trials did not ensure that treatment 
allocation was concealed (McVeigh et al., 2008; Langhorst et al., 2009).  
Comparison of the studies was difficult as the baseline characteristics of the patients were 
heterogeneous, the interventions differed in type, intensity and duration, the methods used 
for assessment of efficacy varied and patients were assessed at different times after spa 
therapy. In particular, the heterogeneity of “spa therapy” makes it difficult to determine 
which form of spa therapy is most effective and no study was designed to compare different 
types of spa care procedures. 
Although the consistency of the results suggests that spa therapy has a therapeutic effect on 
FS, the methodological limitations of the studies preclude any definitive conclusions. 
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Studies conducted according to rigorous methodological criteria in larger numbers of 
patients are needed to determine the potential of spa therapy for FS. 
2.1 Mechanisms of action of spa therapy in FS  
The mechanisms by which immersion in mineral or thermal water or the application of mud 
alleviates suffering in FS are not fully understood. The net benefit is probably the result of a 
combination of factors, among which mechanical, thermal and chemical effects are most 
prominent (Sukenik et al., 1999; Fioravanti et al., 2011). A distinction can be made between 
the non-specific (hydrotherapeutic in a broad sense) mechanisms of simple bathing in hot 
tap water, and specific (hydromineral and crenotherapeutic) mechanisms, which depend on 
the chemical and physical properties of the water used. While the former are well known, 
the latter are difficult to identify and assess. Buoyancy, immersion, resistance and 
temperature all play important roles. Hot stimuli may influence muscle tone and pain 
intensity, helping to reduce muscle spasm and to increase the pain threshold in nerve 
endings. According to the “gate theory”, pain relief may be due to the temperature and 
hydrostatic pressure of water on the skin (Melzack & Wall, 1965 ).  
Thermal stress provokes a series of neuroendocrine reactions (Kuczera & Kokot, 1996), in 
particular release of adrenocorticotropic hormone (ACTH), cortisol, prolactin and growth 
hormone (GH), although it does not alter the circadian rhythm of these hormones. The effect 
of thermal stress on the hypothalamus-pituitary-adrenal axis seems to be particularly 
important for the antiedemigenous and anti-inflammatory effects of corticosteroids. 
Pituitary activation could also be particularly useful in FS, where altered reactivity of the 
hypothalamic-pituitary axis has been observed (Gur et al., 2004).  
The increase in beta-endorphin demonstrated to occur with various spa therapy techniques 
has an analgesic and anti-spastic effect that is particularly important in patients with FS for 
whom pain is the prevalent symptom. Interestingly, it has been found that application of 
mature thermal mud in healthy individuals brings about a rapid increase in plasma beta-
endorphin, which returns to pre-treatment levels within the period of the so-called thermal 
reaction (Cozzi et al., 1995). This increase in beta-endorphin is probably the key factor in the 
mechanism of individual tolerance to thermal mud baths. A recent study has shown a 
reduction in circulating levels of interleukin (IL)-1, prostaglandin E2 (PGE2) and leukotriene 
B4 (LTB4), important mediators of inflammation and pain, in FS patients undergoing a cycle 
of balneotherapy (Ardiç et al., 2007). It has been suggested that inflammatory process 
mediated by cytokines, proteases and inflammatory mediators located in soft body tissue 
may play a role in the pathogenesis of FS, in up to one third of FS patients (Salemi et al., 
2003). This inflammatory process would stimulate subcutaneous nociceptors, resulting in a 
sensation of pain. The detection of IL-1, IL-6 and tumour necrosis factor-(TNF-) in skin of 
one-third of FS patients and elevated plasma PGE2 levels in FS supports this hypothesis 
(Hedenberg-Magnusson et al., 2001). The inhibitory effect of balneotherapy on the 
production and/or release of  IL-1, PGE2 and LTB4 could explain the mechanism of clinical 
benefits of spa therapy in this disorder. Mineral water may also influence the oxidant-
antioxidant system (Eckmekcioglu et al., 2002; Bender et al., 2007), which could be beneficial, 
since oxidative stress disorders have  been described in FS (Bagis et al., 2005). Finally, other 
aspects of the mechanisms of mud packs and balneotherapy in FS need to be considered;  for 
example, the climatic and environmental conditions of spas and the fact that people relax 
away from their daily routines (Sukenik et al., 1999; Fioravanti et al., 2011).  
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3. Conclusion 
In conclusion, spa therapy seems to have a role in the treatment of FS. It cannot substitute 
for conventional therapy but can complement to it. The improvement reported in some 
clinical studies lasts over time. Actually, spa therapy can represent a useful backup to 
pharmacologic treatment of FS or a valid alternative for patients who do not tolerate 
pharmacologic treatments. Future research to clarify the mechanisms of action and the 
effects deriving from the application of thermal treatments are imperative. Additional RCTs 
with high methodological quality concerning the effectiveness of spa therapy in FS are 
necessary in order to obtained strong evidence on the effects of spa therapy. 
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